Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

[1] Pezzi CM(2007)Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Database Ann Surg Oncol 14 166-173

[2] Patel-Parekh L(1992)Classification of metaplastic carcinomas of the breast Pathol Annu 27 89-119

[3] Cole K(1999)Metaplastic breast cancer: prognosis and response to systemic therapy Ann Oncol 10 413-419

[4] Franko J(2001)Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96-102

[5] Klimberg VS(2007)Preoperative chemotherapy for women with operable breast cancer Cochrane Database Syst Rev 2 CD005002-614

[6] Bland K(2014)Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer Ann Surg 260 608-457

[7] Tavassoli FA(2015)Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease J Surg Oncol 112 453-439

[8] Rayson D(2015)Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance) Ann Surg 262 434-304

[9] Adjei AA(2016)Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) Breast Cancer Res Treat 160 297-4422

[10] Suman VJ(2007)Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 4414-443

[1] Pezzi CM(2007)Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Database Ann Surg Oncol 14 166-173

[2] Patel-Parekh L(1992)Classification of metaplastic carcinomas of the breast Pathol Annu 27 89-119

[3] Cole K(1999)Metaplastic breast cancer: prognosis and response to systemic therapy Ann Oncol 10 413-419

[4] Franko J(2001)Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96-102

[5] Klimberg VS(2007)Preoperative chemotherapy for women with operable breast cancer Cochrane Database Syst Rev 2 CD005002-614

[6] Bland K(2014)Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer Ann Surg 260 608-457

[7] Tavassoli FA(2015)Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease J Surg Oncol 112 453-439

[8] Rayson D(2015)Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance) Ann Surg 262 434-304

[9] Adjei AA(2016)Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) Breast Cancer Res Treat 160 297-4422

[10] Suman VJ(2007)Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 4414-443